Journal article
ErbB-2 protein in sera and tumors of breast cancer patients
Breast cancer research and treatment, v 49(3)
01 Jun 1998
PMID: 9776510
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
We compared levels of erbB-2 oncoprotein among three groups: Group I included 60 asymptomatic women; Group II had 51 women with benign breast biopsies; and Group III had 67 women with node-negative breast cancer. Serological levels of erbB-2 protein were measured in all participants; tumor levels were measured for Groups II and III. Forty-three percent of usable tumors (25/58), including three of seven lobular tumors, were erbB-2 positive. Tumor and blood oncoprotein levels were unrelated. Blood levels, however, were positively related to tumor volume, but only when the tumor had both a ductal carcinoma in situ (DCIS) component and an invasive component, suggesting a role for erbB-2 protein in progression of DCIS to invasive carcinoma. In Groups I and II serological levels of erbB-2 protein were directly related to age, and inversely related to having had a live birth. Therefore, a model that determined the threshold levels of serological erbB-2 positivity in Group III included age and nulliparity as independent variables. Only three of the 67 women (4.5%) in Group III were positive for serological erbB-2. In a multivariate model, with serological erbB-2 as the dependent variable, and in which the independent variables included Study Group, there was a statistical trend for younger women, in which Group III had the highest serological levels of erbB-2, followed by Group II, and then Group I. In women who were over the age of 50 years the trend was reversed; i.e., levels of erbB-2 tended to be lowest in Group III, followed by Group II, and finally Group I.[PUBLICATION ABSTRACT]
Metrics
Details
- Title
- ErbB-2 protein in sera and tumors of breast cancer patients
- Creators
- Brenda Breuer - NewYork–Presbyterian HospitalSteven Smith - Columbia UniversityAnn Thor - Evanston HospitalSusan Edgerton - Evanston HospitalMichael Osborne - NewYork–Presbyterian HospitalRichard Minick - NewYork–Presbyterian HospitalHiram Cody - NewYork–Presbyterian HospitalEugene Nowak - NewYork–Presbyterian HospitalArmand Cortese - NewYork–Presbyterian HospitalRache Simmons - NewYork–Presbyterian HospitalWalter Carney - AddgenePaul Brandt-rauf - Columbia University
- Publication Details
- Breast cancer research and treatment, v 49(3)
- Publisher
- Springer Nature B.V
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems; Drexel University
- Web of Science ID
- WOS:000076110000009
- Scopus ID
- 2-s2.0-7344257734
- Other Identifier
- 991019323783104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology